Concern that a front-line class of immunosuppressant drugs used to treat rheumatoid arthritis might increase a patient’s risk of developing herpes zoster (shingles) appears to be unfounded, according to research appearing today in JAMA. Shingles, caused by a reactivation of… Read More ›
Chicago—Numerous studies have demonstrated the benefits of physical activity in reducing the risk of a variety of health problems, including heart disease and Alzheimer disease. Now, new findings suggest that for at least 1 condition, osteoarthritis of the knee, both… Read More ›
Gout’s increasing prevalence along with recent treatment advances have prompted the American College of Rheumatology to issue new clinical guidelines for managing the painful inflammatory disease. Appearing today in Arthritis Care & Research, the guidelines are published in 2 parts…. Read More ›
The once-promising belief that 2 retroviruses that cause leukemia in mice are potential causes of chronic fatigue syndrome in humans has been dismissed by findings from the most rigorous study to date on the link. In the study, published today… Read More ›
Use of muscle relaxants or neuromodulators to manage pain in patients with rheumatoid arthritis delivers less relief than hoped, according to 3 researchers from Australia whose reviews of trial data were released today in The Cochrane Library. Because there is… Read More ›
A new study estimates that more than 32 million people in the United States have antibodies that can attack the body’s own tissues, potentially resulting in inflammation and autoimmune diseases, such as type 1 diabetes, lupus, and rheumatoid arthritis. The… Read More ›
A controversial study that linked chronic fatigue syndrome with a virus has been retracted by the journal Science today, marking a bitter end to a thread of research many patients hoped would lead to effective therapies for the disorder. The… Read More ›
For patients with severe, chronic gout, who do not respond to conventional treatment, pegloticase (Krystexxa) appears to reduce plasma uric acid and pain levels while improving physical function and quality of life. Pegloticase, estimated to cost $2500 per dose, is… Read More ›
